The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.
The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.
复制标题
DOI：
10.1016/j.eururo.2018.09.022
复制
发表时间：
2019-03
期刊：
影响因子：
23.4
通讯作者：
van der Heijden MS
中科院分区：
文献类型：
--
作者：
van Dijk N;Funt SA;Blank CU;Powles T;Rosenberg JE;van der Heijden MS
随着免疫治疗的引入，尿路上皮癌（UC）的糟糕前景发生了变化。尽管如此，许多患者没有反应，并且目前缺乏独特的生物标志物。这种新型免疫疗法的兴起，结合免疫肿瘤反应的复杂生物学，保证了一个全面框架的发展，可以提供在个体患者中发挥作用的重要免疫过程的概述。基于肿瘤和宿主特异性参数制定一个全面的框架，以了解UC的免疫治疗反应。这个框架可以为理性的、生物学驱动的临床试验提供信息，并最终指导我们进行个性化的患者治疗。对UC免疫治疗、临床试验数据和对检查点抑制反应的生物标志物进行了文献综述。在这里，我们提出了UC免疫图，根据目前可用的临床和翻译数据。UC免疫图描述了成功的免疫疗法治疗所需的几个肿瘤和宿主特异性参数。这七个参数是肿瘤外来性、免疫细胞浸润、不存在抑制性检查点、一般表现和免疫状态、不存在可溶性抑制剂、不存在抑制性肿瘤代谢和肿瘤对免疫效应物的敏感性。个体患者参数的纵向整合可能最终导致个性化和动态免疫治疗，以适应推动肿瘤演变的达尔文力量。将多参数生物标志物纳入定量预测模型将是将免疫图整合到日常临床实践中的关键挑战。在这里，我们提出了尿路上皮癌免疫图，描述尿路上皮癌患者及其肿瘤的重要免疫学特征的一种新方法。七个特征决定了产生免疫肿瘤反应的机会。使用这种免疫图，我们的目标是更好地了解为什么有些患者对免疫治疗有反应，而有些患者没有反应，以最终改善抗癌治疗。
The abysmal outlook of urothelial cancer (UC) has changed with the introduction of immunotherapy. Still, many patients do not respond and distinctive biomarkers are currently lacking. The rise of this novel armamentarium of immunotherapy treatments, in combination with the complex biology of an immunological tumor response, warrants the development of a comprehensive framework that can provide an overview of important immunological processes at play in individual patients. To develop a comprehensive framework based on tumor- and host-specific parameters to understand immunotherapy response in UC. This framework can inform rational, biology-driven clinical trials and ultimately guide us toward individualized patient treatment. A literature review was conducted on UC immunotherapy, clinical trial data, and biomarkers of response to checkpoint inhibition. Here, we propose a UC immunogram, based on currently available clinical and translational data. The UC immunogram describes several tumor- and host- specific parameters that are required for successful immunotherapy treatment. These seven parameters are tumor foreignness, immune cell infiltration, absence of inhibitory checkpoints, general performance and immune status, absence of soluble inhibitors, absence of inhibitory tumor metabolism, and tumor sensitivity to immune effectors. Longitudinal integration of individual patient parameters may ultimately lead to personalized and dynamic immunotherapy, to adjust to the Darwinian forces that drive tumor evolution. Incorporating multiparameter biomarkers into quantitative predictive models will be a key challenge to integrate the immunogram into daily clinical practice. Here, we propose the urothelial cancer immunogram, a novel way of describing important immunological characteristics of urothelial cancer patients and their tumors. Seven characteristics determine the chance of having an immunological tumor response. Using this immunogram, we aim to better understand why some patients respond to immunotherapy and some do not, to ultimately improve anticancer therapy.
登录
查看更多内容
基线嗜中性粒细胞与淋巴细胞比率与经ipilmimab治疗的转移性黑色素瘤患者的结果有关。
影响因子：
8.8
作者：
Ferrucci PF;Gandini S;Battaglia A;Alfieri S;Di Giacomo AM;Giannarelli D;Cappellini GC;De Galitiis F;Marchetti P;Amato G;Lazzeri A;Pala L;Cocorocchio E;Martinoli C
通讯作者：
Martinoli C
影响因子：
30.5
作者：
Blackburn, Shawn D.;Shin, Haina;Haining, W. Nicholas;Zou, Tao;Workman, Creg J.;Polley, Antonio;Betts, Michael R.;Freeman, Gordon J.;Vignali, Dario A. A.;Wherry, E. John
通讯作者：
Wherry, E. John
影响因子：
5.4
作者：
Cham, Candace M.;Driessens, Gregory;O'Keefe, James P.;Gajewski, Thomas F.
通讯作者：
Gajewski, Thomas F.
DOI：
10.1111/j.1464-410x.1994.tb07122.x
发表时间：
1994-12-01
期刊：
BRITISH JOURNAL OF UROLOGY
影响因子：
--
作者：
DICKINSON, AJ;FOX, SB;HARRIS, AL
通讯作者：
HARRIS, AL
影响因子：
64.8
作者：
Herbst RS;Soria JC;Kowanetz M;Fine GD;Hamid O;Gordon MS;Sosman JA;McDermott DF;Powderly JD;Gettinger SN;Kohrt HE;Horn L;Lawrence DP;Rost S;Leabman M;Xiao Y;Mokatrin A;Koeppen H;Hegde PS;Mellman I;Chen DS;Hodi FS
通讯作者：
Hodi FS